As reported on Drugs, Eli Lilly has reported positive topline findings from two additional Phase 3 trials of retatrutide, its investigational triple hormone receptor agonist designed to target GIP, GLP-1,…
As reported on PharmaBiz, AstraZeneca has reached an important regulatory milestone in Europe after the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Trixeo…
As reported on PharmaBiz, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation supporting approval of AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate…
As reported on Fierce BioTech, Roche has discontinued development of its investigational T-cell engager (TCE) RG6382 for systemic lupus erythematosus (SLE), following an internal review that concluded the candidate lacked…
Researchers from La Jolla Institute for Immunology (LJI), Scripps Research, and IAVI have reported a major advance in HIV vaccine development, demonstrating an experimental vaccine strategy that produced unusually strong…
As reported on Stock Titan, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Datroway® (datopotamab deruxtecan) as a…
As reported on Reuters, Replimune’s experimental cancer treatment RP1 is facing increased regulatory scrutiny after U.S. Food and Drug Administration (FDA) reviewers expressed concerns about whether current clinical data adequately…
As reported on Pharmaceutical Technology, Kenvue has received US Food and Drug Administration (FDA) approval for an over-the-counter (OTC) pain medication that combines acetaminophen and naproxen sodium in a single…
As reported on Science Daily, a novel CRISPR-driven RNA editing strategy could help overcome one of the biggest challenges in prostate cancer treatment: resistance to immunotherapy. Researchers have demonstrated that…
As reported on Stock Titan, the European Commission has approved Enhertu® (trastuzumab deruxtecan) as a treatment for adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) solid tumors who…
As reported on TechTimes, the U.S. Food and Drug Administration (FDA) has granted Premarket Approval to the TorEx® Lung Perfusion System, a new ex vivo lung perfusion (EVLP) platform developed…
As reported on Clinical Trials Arena, the US Food and Drug Administration (FDA) has released its final guidance on the clinical development of psychedelic therapies, providing drug developers with a…
As reported on PharmaBiz, Alebund Pharmaceuticals has announced the first patient has been enrolled and treated in a global Phase IIb clinical trial evaluating AP306, an investigational therapy for hyperphosphatemia…
As reported on Business Wire, Delcath Systems has announced the enrollment and dosing of the first patient in its global Phase 2 DELUMA clinical trial, marking a significant step in…
As reported on Pharmaceutical Business Review, Affinia Therapeutics has been granted orphan drug designation by the US Food and Drug Administration (FDA) for AFTX-201, an experimental gene therapy being developed…
As reported on Fierce BioTech, Johnson & Johnson has received U.S. Food and Drug Administration (FDA) clearance for its Ottava Robotic Surgical System, marking a significant step in the company’s…
As reported by The Manila Times, Abeona Therapeutics has announced that Cincinnati Children’s Hospital Medical Center has been designated as the seventh Qualified Treatment Center (QTC) authorized to administer ZEVASKYN®…
A newly reported case from Nanchang University suggests that efgartigimod, a neonatal Fc receptor (FcRn) blocker approved for generalized myasthenia gravis, may offer a promising treatment option for patients who…
Merck has reported positive topline findings from the Phase 3 KEYNOTE-C93 trial, demonstrating that pembrolizumab (KEYTRUDA®) significantly extended progression-free survival (PFS) compared with standard platinum-based chemotherapy in patients with mismatch…
If you or a loved one has ever survived a stroke, you know that the hardest part of the journey often begins after you leave the hospital. Emergency room doctors…
As reported on PharmaBiz, AtaiBeckley has announced a key milestone in the development of its investigational depression therapy, VLS-01, with the final participant now dosed in the company’s Phase 2b…
As reported on Vermont Biz, researchers at the University of Vermont (UVM) and biotechnology company RS Oncology have reported encouraging results from an early-stage clinical trial of a novel treatment…
As reported by The Manila Times, the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Elevar Therapeutics regarding its new drug application for the…
As covered by Fairfax Times, Novo Nordisk has reported encouraging long-term findings for its investigational hemophilia A therapy denecimig (Mim8), with interim results from the Phase 3 FRONTIER4 extension study…
Our friends at Heal Canada have launched the newest edition of their magazine, E3 Advocacy! Their digital publication focuses on the importance of patient advocacy, patient stories, and bridging knowledge…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
